Literature DB >> 19954248

Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites.

Igor Shamovsky1, Chris de Graaf, Lisa Alderin, Malena Bengtsson, Håkan Bladh, Lena Börjesson, Stephen Connolly, Hazel J Dyke, Marco van den Heuvel, Henrik Johansson, Bo-Göran Josefsson, Anna Kristoffersson, Tero Linnanen, Annea Lisius, Roope Männikkö, Bo Nordén, Steve Price, Lena Ripa, Didier Rognan, Alexander Rosendahl, Marco Skrinjar, Klaus Urbahns.   

Abstract

The metabolic stability and selectivity of a series of CCR8 antagonists against binding to the hERG ion channel and cytochrome Cyp2D6 are studied by principal component analysis. It is demonstrated that an efficient way of increasing metabolic stability and selectivity of this series is to decrease compound lipophilicity by engineering nondesolvation related attractive interactions with CCR8, as rationalized by three-dimensional receptor models. Although such polar interactions led to increased compound selectivity, such a strategy could also jeopardize the DMPK profile of compounds. However, once increased potency is found, the lipophilicity can be readjusted by engineering hydrophobic substituents that fit to CCR8 but do not fit to hERG. Several such lipophilic fragments are identified by two-dimensional fragment-based QSAR analysis. Electrophysiological measurements and site-directed mutagenesis studies indicated that the repulsive interactions of these fragments with hERG are caused by steric hindrances with residue F656.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19954248     DOI: 10.1021/jm900713y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Palladium-Catalyzed Methylation of Aryl, Heteroaryl, and Vinyl Boronate Esters.

Authors:  Alexander M Haydl; John F Hartwig
Journal:  Org Lett       Date:  2019-02-14       Impact factor: 6.005

2.  Pharmacological and electrophysiological characterization of AZSMO-23, an activator of the hERG K(+) channel.

Authors:  R Mannikko; M H Bridgland-Taylor; H Pye; S Swallow; N Abi-Gerges; M J Morton; C E Pollard
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

3.  Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice.

Authors:  Felix Heymann; Linda Hammerich; Dunja Storch; Matthias Bartneck; Sebastian Huss; Vanessa Rüsseler; Nikolaus Gassler; Sergio A Lira; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Hepatology       Date:  2012-01-13       Impact factor: 17.425

Review 4.  Pharmacological modulation of chemokine receptor function.

Authors:  D J Scholten; M Canals; D Maussang; L Roumen; M J Smit; M Wijtmans; C de Graaf; H F Vischer; R Leurs
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

5.  Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.

Authors:  Katarina Roos; Anders Hogner; Derek Ogg; Martin J Packer; Eva Hansson; Kenneth L Granberg; Emma Evertsson; Anneli Nordqvist
Journal:  J Comput Aided Mol Des       Date:  2015-11-16       Impact factor: 3.686

6.  Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H₄ and the ion channel serotonin 5-HT₃A.

Authors:  Mark H P Verheij; Chris de Graaf; Gerdien E de Kloe; Saskia Nijmeijer; Henry F Vischer; Rogier A Smits; Obbe P Zuiderveld; Saskia Hulscher; Linda Silvestri; Andrew J Thompson; Jacqueline E van Muijlwijk-Koezen; Sarah C R Lummis; Rob Leurs; Iwan J P de Esch
Journal:  Bioorg Med Chem Lett       Date:  2011-07-02       Impact factor: 2.823

7.  C-H methylation of heteroarenes inspired by radical SAM methyl transferase.

Authors:  Jinghan Gui; Qianghui Zhou; Chung-Mao Pan; Yuki Yabe; Aaron C Burns; Michael R Collins; Martha A Ornelas; Yoshihiro Ishihara; Phil S Baran
Journal:  J Am Chem Soc       Date:  2014-03-21       Impact factor: 15.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.